The DOI matches its Crossref record; 299 of the 299 references it cites were found in a registry or an index.
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Open accessAbstract
Mesenchymal stem cells (MSC) comprise a heterogeneous population of rapidly proliferating cells that can be isolated from adult (e.g., bone marrow, adipose tissue) as well as fetal (e.g., umbilical cord) tissues (termed bone marrow (BM)-, adipose tissue (AT)-, and umbilical cord (UC)-MSC, respectively) and are capable of differentiation into a wide range of non-hematopoietic cell types. An additional, unique attribute of MSC is their ability to home to tumor sites and to interact with the local supportive microenvironment which rapidly conceptualized into MSC-based experimental cancer cytotherapy at the turn of the century. Towards this purpose, both naïve (unmodified) and genetically modified MSC (GM-MSC; used as delivery vehicles for the controlled expression and release of antitumorigenic molecules) have been employed using well-established in vitro and in vivo cancer models, albeit with variable success. The first approach is hampered by contradictory findings regarding the effects of naïve MSC of different origins on tumor growth and metastasis, largely attributed to inherent biological heterogeneity of MSC as well as experimental discrepancies. In the second case, although the anti-cancer effect of GM-MSC is markedly improved over that of naïve cells, it is yet apparent that some protocols are more efficient against some types of cancer than others. Regardless, in order to maximize therapeutic consistency and efficacy, a deeper understanding of the complex interaction between MSC and the tumor microenvironment is required, as well as examination of the role of key experimental parameters in shaping the final cytotherapy outcome. This systematic review represents, to the best of our knowledge, the first thorough evaluation of the impact of experimental anti-cancer therapies based on MSC of human origin (with special focus on human BM-/AT-/UC-MSC). Importantly, we dissect the commonalities and differences as well as address the shortcomings of work accumulated over the last two decades and discuss how this information can serve as a guide map for optimal experimental design implementation ultimately aiding the effective transition into clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Representation of common cancer types in MSC-based cytotherapy studies compiled in this review in comparison to global cancer incidences (clinical relevance). The most frequently targeted tumors in cancer cytotherapy studies have been ranked in descending order of worldwide cancer incidence (2012 data) [122] from left to right on the x axis. Global cancer incidence rates are depicted as solid line symbols (boxed values), while the frequencies of tumors targeted by unmodified/naïve MSC (n-MSC) or genetically modified MSC (GM-MSC; see also the “Genetically modified MSC as delivery vehicles for antitumorigenic molecules—overview and meta-analysis results” section) in experimental cancer cytotherapy (CT), as determined by our meta-analysis, are represented by black (n-MSC CT) or white (GM-MSC CT) columns, respectively. Sample sizes: N = 79/N = 67 for n-MSC- and GM-MSC-based work, respectively. For each cancer type, the difference in height between the solid line symbols and the column bars denotes the divergence in representation of global cancer incidence by CT work, with positive differences (global % > MSC CT %) signifying under-representation, and negative ones (MSC CT % > global %) over-representation of cancer incidence. For example, the two most under-represented tumors targeted by n-MSC CT are those of lung as well of liver/stomach/pancreas (HGP) (by 12.3% and 8.5%, respectively), while the most over-represented ones are those of breast and brain (difference of − 11.3 and − 8.3, respectively), see the main text (the “Relevance of preclinical cancer cytotherapy targeting to global cancer incidence” section) for further discussion. Overall, the data suggest that in order for experimental CT work to become more clinically relevant, more focus should be put on the following, under-represented tumor targets: * Hepatic/gastric/pancreatic (HGP) tumors (using both n-MSC and GM-MSC). * n-MSC-based lung cancer cytotherapy. * Colorectal cancer targeted by both n-MSC (especially UC-MSC) and GM-MSC. * Prostate cancer targeted by GM-MSC (especially UC-MSC), as well as n-MSC. * GM-UC-MSC-based brain tumor cytotherapy](https://figures.cochat.ai/paper-figures/d435cb355c474be297a871da863d74ea/mesenchymal-stem-cells-in-preclinical-cancer-cytotherapy-a-systematic-review-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo and in vitro studies have confirmed that numerous factors such as monocyte chemotactic protein-1 (MCP-1 or CCL2) in breast cancer or stromal cell-derived factor-1 (SDF-1) in prostate, colorectal and breast cancer that are produced by tumour and inflammatory cells promote the homing and migration of MSCs into the tumour microenvironment [23].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pro-metastatic effect of MSCs has been proven in breast cancer (CCL5 and IL-17B), hepatocellular carcinoma (MMP2) and osteosarcoma (CXCR4/VEGF axis) [23].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSCs and cancer cells are thought to use similar signaling pathways regulating self-renewal and differentiation, namely the Wnt/β-catenin, Notch, Shh and BMP pathways [23], [54].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other possible mechanisms that contribute to the anti-tumour potential of MSCs include apoptosis caused by upregulation of TRAIL, G1 arrest, and expression of tumour suppressor genes [23] (Fig. 2).”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Once MSCs are recruited by cancer cells, they enhance the production of factors like TGF-β, VEGF, SDF-1, and CCL5 or microparticles like exosomes that can either induce or inhibit tumour growth; owing to this bimodal interaction, MSCs have been described as a ”double-edged sword” [23].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [23]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Li, H., Hu, J., Zhao, J., Liu, J., Ouyang, W., Yang, C., Gong, N., Du, L., Khanal, A., & Chen, L. (2013) · BioMed Research International · doi:10.1155/2013/438243 · Cited by 72
RetractedHan, I., Yun, M., Kim, E., Kim, B., Jung, M., & Kim, S. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt443 · Cited by 59
RetractedMultilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Stöckl, S., Göttl, C., Grifka, J., & Grässel, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350089 · Cited by 4,656
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Research works printed but not linked: 1
- Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (“clinging ductal carcinoma in situ”). Cancer. 2000;88:2072–81. · doi:10.1002/(sici)1097-0142(20000501)88:9<2072::aid-cncr13>3.0.co;2-h
Cited by
Stem cells: past, present, and future
Zakrzewski, W., Dobrzyński, M., Szymonowicz, M., & Rybak, Z. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1165-5 · Cited by 1,834
Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Zhao, Y., Shen, M., Wu, L., Yang, H., Yao, Y., Yang, Q., Du, J., Liu, L., Li, Y., & Bai, Y. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06110-6 · Cited by 431
Chu, D.-T., Nguyen, T. T., Tien, N. L. B., Tran, D.-K., Jeong, J.-H., Anh, P. G., Thanh, V. V., Truong, D. T., & Dinh, T. C. (2020) · Cells · doi:10.3390/cells9030563 · Cited by 216
Cell primitive-based biomimetic functional materials for enhanced cancer therapy
Luo, G.-F., Chen, W.-H., Zeng, X., & Zhang, X.-Z. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00152j · Cited by 193
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
“A recent systematic review by Christodoulou et al addresses these issues in the settings of preclinical cancer cytotherapy [225].”
Background
Metadata
- Authors
- Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V.
- Affiliations
- National Hellenic Research Foundation (GR)
- Corresponding author
- Zoumpourlis, Vassilis
- Venue
- Stem Cell Research & Therapy
- Published
- 2018-12
- Volume
- 9
- Issue
- 1
- Pages
- 336-336
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC6286545
- OpenAlex
- W2904058752
- Cited by
- 122
- References
- 299
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 19 · 2023: 21 · 2022: 18 · 2021: 16 · 2020: 18 · 2019: 10 · 2018: 1
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- National Hellenic Research Foundation Helios Repository (National Hellenic Research Foundation) (submittedVersion)
- Funders
- General Secretariat for Research and Technology (2400)
- State Scholarships Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, human umbilical cord mesenchymal stem cells, tumor microenvironment, tumor growth, metastasis, preclinical cancer models, experimental design
- MeSH terms
- Animals, Humans, Neoplasms, Phenotype, Mesenchymal Stem Cell Transplantation, Tumor Microenvironment, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. https://app.cochat.ai/papers/10.1186/s13287-018-1078-8
- The paper
- Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018). Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-018-1078-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.